Apex Biotechnology Corp. (TPE:1733)

Apex Biotechnology Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,960	1,852	1,677	2,244	2,132	2,005
Revenue Growth (YoY)	8.38%	10.48%	-25.29%	5.28%	6.30%	-8.80%
Cost of Revenue	1,403	1,331	1,145	1,667	1,560	1,553
Gross Profit	557.38	521.34	531.12	576.84	571.51	452.22
Selling, General & Admin	228.15	231.31	224.26	234.83	216.77	198.49
Research & Development	159.65	161.52	163.33	165.45	153.29	150.77
Operating Expenses	402.13	392.88	389.4	400.28	366.56	348.9
Operating Income	155.26	128.46	141.72	176.56	204.95	103.33
Interest Expense	-3.48	-3.64	-4.39	-5.4	-12.53	-10.28
Interest & Investment Income	6.82	4.34	3.2	1.15	2.01	2.72
Currency Exchange Gain (Loss)	-4.74	17.6	18.97	54.71	-58.6	-3.56
Other Non Operating Income (Expenses)	2.09	2.13	3.2	0.32	17.41	11.6
EBT Excluding Unusual Items	155.95	148.9	162.7	227.35	153.23	103.82
Gain (Loss) on Sale of Investments	20.53	4.23	-3.96	-2.89	31.7	6.8
Asset Writedown	-	-	-17.78	-24.89	-	-
Pretax Income	176.48	153.13	140.96	199.58	184.94	110.62
Income Tax Expense	25.14	25.02	25.25	18.12	-17.35	15.99
Earnings From Continuing Operations	151.34	128.1	115.71	181.45	202.29	94.63
Minority Interest in Earnings	-0.03	-0.11	0.07	0.33	-0.07	0.17
Net Income	151.31	128	115.78	181.79	202.22	94.8
Net Income to Common	151.31	128	115.78	181.79	202.22	94.8
Net Income Growth	44.56%	10.55%	-36.31%	-10.11%	113.33%	-16.74%
Shares Outstanding (Basic)	100	100	100	100	100	100
Shares Outstanding (Diluted)	100	100	100	101	106	113
Shares Change (YoY)	0.17%	0.08%	-0.34%	-4.70%	-6.53%	0.05%
EPS (Basic)	1.51	1.28	1.16	1.82	2.03	0.95
EPS (Diluted)	1.50	1.27	1.15	1.81	1.93	0.87
EPS Growth	44.25%	10.44%	-36.46%	-6.16%	120.97%	-16.21%
Free Cash Flow	205.19	300.43	208.48	-9.97	153.28	235.35
Free Cash Flow Per Share	2.04	2.99	2.08	-0.10	1.45	2.08
Dividend Per Share	1.200	1.200	1.100	1.400	1.300	1.100
Dividend Growth	9.09%	9.09%	-21.43%	7.69%	18.18%	-
Gross Margin	28.44%	28.15%	31.68%	25.70%	26.81%	22.55%
Operating Margin	7.92%	6.94%	8.45%	7.87%	9.62%	5.15%
Profit Margin	7.72%	6.91%	6.91%	8.10%	9.49%	4.73%
Free Cash Flow Margin	10.47%	16.22%	12.44%	-0.44%	7.19%	11.74%
EBITDA	206.39	182.03	206.52	260.08	291.6	199.83
EBITDA Margin	10.53%	9.83%	12.32%	11.59%	13.68%	9.96%
D&A For EBITDA	51.13	53.56	64.8	83.52	86.65	96.51
EBIT	155.26	128.46	141.72	176.56	204.95	103.33
EBIT Margin	7.92%	6.94%	8.45%	7.87%	9.62%	5.15%
Effective Tax Rate	14.24%	16.34%	17.91%	9.08%	-	14.45%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.